This clinical trial is focused on studying a type of cancer called squamous cell carcinoma of the head and neck. This cancer affects areas such as the mouth, throat, and voice box. The study is testing a treatment that combines two medications: nivolumab and cisplatin, along with radiotherapy. Nivolumab is a medication that helps the immune system fight cancer, while cisplatin is a chemotherapy drug that kills cancer cells. The purpose of the study is to see if adding nivolumab to the standard treatment of cisplatin and radiotherapy can improve outcomes for patients.
Participants in the study will receive treatment through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will compare the effects of the combination of nivolumab and cisplatin with radiotherapy to the effects of cisplatin and radiotherapy alone. Some participants will receive a placebo instead of nivolumab to help researchers understand the true effects of the medication. The study will last for several months, and participants will have regular check-ups and imaging tests to monitor their health and the progress of the cancer.
The main goal is to determine if the combination treatment can help patients live longer without the cancer coming back. Researchers will also look at overall survival rates and any side effects that may occur. This study is important because it could lead to better treatment options for people with high-risk squamous cell carcinoma of the head and neck who have already had surgery to remove the cancer.
Belgium 
France 
Greece 
Poland 
Spain 